Inmune Bio, Inc. (INMB) stock
Close on Nov 12, 2026Market cap $29.14MP/E –Yield –
Inmune Bio, Inc. grew revenue 257.1% to $50.00K over fiscal 2025. Free cash flow was -$23.62M. At the latest close the market valued the company at $29.14M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $29.14M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.61
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $50.00K
- Net income
- -$16.67M
- EPS, diluted
- -$0.62
- Free cash flow
- -$23.62M
- Book value per share
- $0.65
- Diluted shares
- 28M
Trading
- Previous close
- $1.10
- Open
- $1.10
- Day's range
- $1.01 – $1.10
- Volume
- 410,240
- Average volume (20 days)
- 275,200
- Beta (5 years)
- 1.33
- 52-week range
- $1.01 – $2.60
- RSI (14 days)
- 21.9
- Volatility (1 year)
- 74.1%
- Relative volume
- 1.05×
- WACC
- 11.5%
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | INMB | S&P 500 | Difference | INMB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -41.0% | -2.7% | −38.3 pts | ||
| 3 months | -48.5% | -1.7% | −46.8 pts | ||
| Year to date | -32.7% | +11.9% | −44.6 pts | ||
| 1 year | -30.9% | +12.0% | −42.9 pts | ||
| 3 years | -84.7% | +78.2% | −162.9 pts | -46.5% | +21.2% |
| 5 years | -92.8% | +73.2% | −166.0 pts | -40.9% | +11.6% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Inmune Bio filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- News
- News
About Inmune Bio
Biological Products, (No Diagnostic Substances)
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing therapies that reprogram the innate immune system to treat diseases driven by chronic inflammation and immune dysfunction. Its clinical pipeline includes CORDStrom, an allogeneic, human umbilical cord-derived mesenchymal stromal cell therapy for recessive dystrophic epidermolysis bullosa; XPro1595, a biologic targeting neuroinflammation in early Alzheimer’s disease by neutralizing soluble tumor necrosis factor; and INKmune, a natural killer cell-priming therapeutic platform evaluated for hematologic malignancies and metastatic castrate-resistant prostate cancer. The company's therapies are designed for patients suffering from severe inflammatory conditions, neurodegenerative disorders, and oncology indications.
Company profile, executives and historyInmune Bio stock: common questions
What is Inmune Bio's stock price?
INMB closed at $1.05 on Nov 12, 2026, down 4.55% on the day. Over the past 52 weeks it traded between $1.01 and $2.60.
What is Inmune Bio's market cap?
Inmune Bio was worth $29.14M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is INMB's P/E ratio?
Inmune Bio lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.62), so it has no meaningful P/E ratio.
How much revenue does Inmune Bio make?
Inmune Bio reported revenue of $50.00K for fiscal 2025, up 257.1% from a year earlier.
Does Inmune Bio pay a dividend?
No. Inmune Bio has not paid a cash dividend over the last twelve months.
How has INMB stock performed over the past year?
Including dividends, INMB returned -30.9% over the past year, against +12.0% for the S&P 500.
How many INMB shares are sold short?
3M shares were sold short at the latest FINRA report, 11.50% of the float, or 14.4 days of average trading volume.
Who are Inmune Bio's competitors?
Companies most similar to Inmune Bio by business, industry and size include AIM, ALLO, ENTX, AVTX, ALT.
See a number that looks wrong?